DCTH - Delcath Systems Inc
Delcath Systems Inc Logo

DCTH - Delcath Systems Inc

https://www.delcath.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-09 (Snapshot)

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.

52W High
$18.23
52W Low
$8.08
MA Status:
50D: Above 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.85
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
129.44
Forward P/E (<15 better)
14.84
EV/EBITDA (<8 favorable)
62.11
EV/Revenue (<3 favorable)
4.66
P/S (TTM) (<3 favorable)
5.80
P/B (<3 favorable)
3.88
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
2.72%
Institutions (25–75% balanced)
52.75%
Shares Outstanding
34,981,300
Float
34,028,700
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
70,240,000
Gross Profit (TTM)
60,311,000
EPS (TTM)
0.09
Profit Margin (>10% good)
0.03%
Operating Margin (TTM) (higher better)
0.11%
ROE (TTM) (>15% strong)
0.04%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
2.11
Momentum
Bearish momentum
Value
0.0255
Previous
0.0682
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025